Cargando…
Conivaptan: Evidence supporting its therapeutic use in hyponatremia
INTRODUCTION: The available treatment options for euvolemic and hypervolemic hyponatremia are limited, and consist mainly of fluid restriction, diuresis, or hypertonic solutions. Most of these therapies are neither well tolerated nor totally effective, and many are associated with significant advers...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2899773/ https://www.ncbi.nlm.nih.gov/pubmed/20694067 |
_version_ | 1782183557856231424 |
---|---|
author | Li-Ng, Melissa Verbalis, Joseph G |
author_facet | Li-Ng, Melissa Verbalis, Joseph G |
author_sort | Li-Ng, Melissa |
collection | PubMed |
description | INTRODUCTION: The available treatment options for euvolemic and hypervolemic hyponatremia are limited, and consist mainly of fluid restriction, diuresis, or hypertonic solutions. Most of these therapies are neither well tolerated nor totally effective, and many are associated with significant adverse effects. Vasopressin receptor antagonists, also known as vaptans, are a new class of agents that now offer an additional treatment option for hyponatremic patients. Conivaptan hydrochloride, a competitive antagonist of vasopressin V1a and V2 receptors, is the first agent in this class to be approved for treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients. AIMS: This review critically assesses the evidence that support the use of conivaptan for the treatment of patients with euvolemic and hypervolemic hyponatremia. EVIDENCE REVIEW CONCLUSION: Conivaptan is effective in raising serum sodium levels in a predictable and safe fashion in euvolemic and hypervolemic hyponatremic patients. Conivaptan provides the first molecularly targeted approach for correcting hyponatremia in hospitalized patients. |
format | Text |
id | pubmed-2899773 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-28997732010-08-05 Conivaptan: Evidence supporting its therapeutic use in hyponatremia Li-Ng, Melissa Verbalis, Joseph G Core Evid Review INTRODUCTION: The available treatment options for euvolemic and hypervolemic hyponatremia are limited, and consist mainly of fluid restriction, diuresis, or hypertonic solutions. Most of these therapies are neither well tolerated nor totally effective, and many are associated with significant adverse effects. Vasopressin receptor antagonists, also known as vaptans, are a new class of agents that now offer an additional treatment option for hyponatremic patients. Conivaptan hydrochloride, a competitive antagonist of vasopressin V1a and V2 receptors, is the first agent in this class to be approved for treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients. AIMS: This review critically assesses the evidence that support the use of conivaptan for the treatment of patients with euvolemic and hypervolemic hyponatremia. EVIDENCE REVIEW CONCLUSION: Conivaptan is effective in raising serum sodium levels in a predictable and safe fashion in euvolemic and hypervolemic hyponatremic patients. Conivaptan provides the first molecularly targeted approach for correcting hyponatremia in hospitalized patients. Dove Medical Press 2010-06-15 2009 /pmc/articles/PMC2899773/ /pubmed/20694067 Text en © 2009 Li-Ng and Verbalis, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Review Li-Ng, Melissa Verbalis, Joseph G Conivaptan: Evidence supporting its therapeutic use in hyponatremia |
title | Conivaptan: Evidence supporting its therapeutic use in hyponatremia |
title_full | Conivaptan: Evidence supporting its therapeutic use in hyponatremia |
title_fullStr | Conivaptan: Evidence supporting its therapeutic use in hyponatremia |
title_full_unstemmed | Conivaptan: Evidence supporting its therapeutic use in hyponatremia |
title_short | Conivaptan: Evidence supporting its therapeutic use in hyponatremia |
title_sort | conivaptan: evidence supporting its therapeutic use in hyponatremia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2899773/ https://www.ncbi.nlm.nih.gov/pubmed/20694067 |
work_keys_str_mv | AT lingmelissa conivaptanevidencesupportingitstherapeuticuseinhyponatremia AT verbalisjosephg conivaptanevidencesupportingitstherapeuticuseinhyponatremia |